Oncotelic Therapeutics CEO's Patent Portfolio and Drug Development Expertise Highlighted in Audio Feature

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) is featured in a new NetworkNewsAudio Audio Press Release that highlights the company's innovative therapeutics pipeline and its potential for strong market growth. The feature emphasizes the leadership of chair and CEO Dr. Vuong Trieu, who has filed more than 500 patent applications and holds 75 issued patents spanning oncology, immunotherapy, and nanomedicine. Dr. Trieu's previous development of Abraxane, a nanotechnology-based formulation that transformed treatment for breast, lung, and pancreatic cancers, and his advancement of Cynviloq, a novel micellar paclitaxel therapy, underscore his expertise and track record in pioneering cancer treatments.

The audio release positions Oncotelic to advance groundbreaking therapies with strong market potential, leveraging Dr. Trieu's extensive intellectual property portfolio and experience in drug development. This focus on high-unmet-need cancers and rare pediatric indications aligns with the company's mission as a clinical-stage biopharmaceutical entity. Beyond its internal programs, Oncotelic benefits from joint ventures such as GMP Bio, in which it owns 45%, further complementing its strategic position in oncology and rare disease therapeutics. The full press release can be accessed at https://ibn.fm/2Ir6y, and additional news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC.

InvestorWire, the platform behind this feature, is a specialized communications brand within the Dynamic Brand Portfolio @IBN, offering advanced wire-grade press release syndication and a full array of tailored corporate communications solutions. For more information on InvestorWire, visit https://www.InvestorWire.com, and review the full terms of use and disclaimers at https://www.InvestorWire.com/Disclaimer. This coverage underscores the importance of Oncotelic's pipeline and leadership in driving future growth and addressing critical healthcare challenges.